Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare

Area of Science:

• Cardiology
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is standard after percutaneous coronary intervention (PCI), but optimal regimens remain challenging.
• Uncertainty exists regarding DAPT in high-bleeding-risk patients, including the elderly and those on anticoagulation.
• Bleeding risk, previously underestimated, is now recognized as a major driver of morbidity and mortality post-PCI.

Purpose of the Study:

• To critically evaluate the available evidence for DAPT in challenging clinical scenarios.
• To address the dilemma of balancing ischemic and bleeding risks with novel antiplatelet agents and anticoagulants.
• To provide clarity on DAPT recommendations for patients at high risk of bleeding post-PCI.

Main Methods:

• Review of current literature and clinical trial data on DAPT after PCI.
• Analysis of evidence concerning bleeding risk versus ischemic risk in specific patient cohorts.
• Synthesis of expert consensus and guideline recommendations for DAPT in complex cases.

Main Results:

• Significant uncertainty persists regarding optimal DAPT strategies in elderly patients and those requiring anticoagulation.
• Existing data often lacks focus on bleeding risk, leading to conflicting recommendations.
• The review highlights a paucity of robust data for guiding DAPT in high-bleeding-risk populations.

Conclusions:

• There is a critical need for more research into DAPT strategies for high-bleeding-risk patients undergoing PCI.
• Clinicians must carefully weigh the risks and benefits of potent antiplatelet agents and anticoagulants.
• Evidence-based guidelines are needed to navigate DAPT decisions in complex, aging populations.